SOBI Stock Analysis: Swedish Orphan Biovitrum | ST
Drug Manufacturers - Specialty & Generic | ST, Sweden | Market Cap: 166.614m SEK | 12M Return: 56.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 199M
EPS Trend: 77.9%
Qual. Beats: 0
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Swedish Orphan Biovitrum AB (publ) (SOBI) is a Sweden-based biopharmaceutical company founded in 1939 and headquartered in Stockholm. It develops, manufactures, and commercialises medicines in three core therapeutic areas: Haematology, Immunology, and Specialty Care, serving patients across Europe, North America, the Middle East, Asia, and Australia.
Its portfolio includes branded therapies for rare and serious conditions such as haemophilia A and B (Elocta/Eloctate, Alprolix, ALTUVOCT), paroxysmal nocturnal haemoglobinuria (Aspaveli/Empaveli), immune thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and various inflammatory and rare metabolic disorders (Kineret, Orfadin). SOBI also markets Synagis for RSV prevention in infants, oncology products (VONJO, Zynlonta), and additional specialty medicines (Akynzeo, Jyseleca, Tegsedi, Waylivra), while manufacturing drug substances for Pfizers ReFacto AF/Xyntha. The company holds collaboration agreements with Sanofi, Apellis Pharmaceuticals, ADC Therapeutics, and Cartesian Therapeutics.
As a large-cap European biopharma, SOBI operates a specialty-care business model focused on rare diseases and orphan indications, a segment that typically benefits from extended market exclusivity, premium pricing, and lower patient-population competition. Its revenue model relies on both direct commercialisation of proprietary drugs and royalty/manufacturing income from partner products, giving it a mix of high-growth launched therapies and more stable contracted cash flows.
- Haematology revenue grows on ALTUVOCT and Elocta demand
- Hemlibra competition pressures haemophilia pricing and market share
- Aspaveli PNH launch drives rare haematology segment expansion
| Net Income: 921.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.66 > 1.0 |
| NWC/Revenue: -22.13% < 20% (prev -0.94%; Δ -21.19% < -1%) |
| CFO/TA 0.09 > 3% & CFO 7.39b > Net Income 921.0m |
| Net Debt (18.5b) to EBITDA (11.3b): 1.64 < 3 |
| Current Ratio: 0.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (349.4m) vs 12m ago 0.69% < -2% |
| Gross Margin: 44.16% > 18% (prev 74.93%; Δ -30.77% > 0.5%) |
| Asset Turnover: 38.26% > 50% (prev 37.42%; Δ 0.84% > 0%) |
| Interest Coverage Ratio: 1.85 > 6 (EBIT TTM 1.38b / Interest Expense TTM 742.0m) |
| A: -0.08 (Total Current Assets 15.3b - Total Current Liabilities 21.7b) / Total Assets 81.3b |
| B: 0.29 (Retained Earnings 23.7b / Total Assets 81.3b) |
| C: 0.02 (EBIT TTM 1.38b / Avg Total Assets 75.7b) |
| D: 0.99 (Book Value of Equity 40.4b / Total Liabilities 40.9b) |
| Altman-Z'' = 1.59 = BB |
| DSRI: 1.23 (Receivables 9.28b/6.83b, Revenue 29.0b/26.2b) |
| GMI: 1.70 (GM 74.93% / 44.16%) |
| AQI: 0.98 (AQ_t 0.79 / AQ_t-1 0.81) |
| SGI: 1.10 (Revenue 29.0b / 26.2b) |
| TATA: -0.08 (NI 921.0m - CFO 7.39b) / TA 81.3b) |
| Beneish M = -2.15 (Cap -4..+1) = BB |
As of July 14, 2026, the stock is trading at SEK 461.20 with a total of 260,583 shares traded. Over the past week, the price has changed by -3.92%, over one month by +6.02%, over three months by +13.60% and over the past year by +56.13%.
Current recommended Stop Loss: 438.70 (which is 4.9% or 2 ATR below the current price).
Swedish Orphan Biovitrum has no consensus analysts rating.
P/E Trailing = 181.7424
P/E Forward = 26.0417
P/S = 5.7539
P/B = 4.1028
P/EG = 0.3466
Revenue TTM = 29.0b SEK
EBIT TTM = 1.38b SEK
EBITDA TTM = 11.3b SEK
Long Term Debt = 7.65b SEK (from longTermDebt, last quarter)
Short Term Debt = 11.1b SEK (from shortTermDebt, last quarter)
Debt = 19.4b SEK (from shortLongTermDebtTotal, last quarter) + Leases 381.0m
Net Debt = 18.5b SEK (calculated: Debt 19.4b - CCE 940.0m)
Enterprise Value = 185b SEK (167b + Debt 19.4b - CCE 940.0m)
Interest Coverage Ratio = 1.85 (Ebit TTM 1.38b / Interest Expense TTM 742.0m)
EV/FCF = 27.60x (Enterprise Value 185b / FCF TTM 6.71b)
FCF Yield = 3.62% (FCF TTM 6.71b / Enterprise Value 185b)
FCF Margin = 23.16% (FCF TTM 6.71b / Revenue TTM 29.0b)
Net Margin = 3.18% (Net Income TTM 921.0m / Revenue TTM 29.0b)
Gross Margin = 44.16% ((Revenue TTM 29.0b - Cost of Revenue TTM 16.2b) / Revenue TTM)
Gross Margin QoQ = 75.68% (prev 49.43%)
Tobins Q-Ratio = 2.28 (Enterprise Value 185b / Total Assets 81.3b)
Interest Expense / Debt = 3.82% (Interest Expense 742.0m / Debt 19.4b)
Taxrate = 21.59% (363.0m / 1.68b)
NOPAT = 1.08b (EBIT 1.38b * (1 - 21.59%))
Current Ratio = 0.70 (Total Current Assets 15.3b / Total Current Liabilities 21.7b)
Debt / Equity = 0.48 (Debt 19.4b / totalStockholderEquity, last quarter 40.4b)
Debt / EBITDA = 1.64 (Net Debt 18.5b / EBITDA 11.3b)
Debt / FCF = 2.76 (Net Debt 18.5b / FCF TTM 6.71b)
Total Stockholder Equity = 38.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.22% (Net Income 921.0m / Total Assets 81.3b)
RoE = 2.41% (Net Income TTM 921.0m / Total Stockholder Equity 38.3b)
RoCE = 3.00% (EBIT 1.38b / Capital Employed (Equity 38.3b + L.T.Debt 7.65b))
RoIC = 1.55% (NOPAT 1.08b / Invested Capital 69.8b)
WACC = 7.54% (E(167b)/V(186b) * Re(8.07%) + D(19.4b)/V(186b) * Rd(3.82%) * (1-Tc(0.22)))
Discount Rate = 8.07% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.29 | Cagr: 0.84%
[DCF] Terminal Value 77.97% ; FCFF base≈6.16b ; Y1≈7.06b ; Y5≈10.4b
[DCF] Fair Price = 398.3 (EV 156b - Net Debt 18.5b = Equity 138b / Shares 345.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 77.92 | EPS CAGR: 28.39% | SUE: 0.21 | # QB: 0
Revenue Correlation: 98.43 | Revenue CAGR: 13.84% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.56 | Chg30d=+10.56% | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=5.28 | Chg30d=+3.94% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=19.15 | Chg30d=+2.53% | Revisions=+50% | GrowthEPS=+14.1% | GrowthRev=+14.4%
EPS next Year (2027-12-31): EPS=22.73 | Chg30d=+1.26% | Revisions=+17% | GrowthEPS=+18.7% | GrowthRev=+13.2%
[Analyst] Revisions Ratio: +55% (up=7, down=1)